GlassScriptPhysician profile
William G Jackson
NPI 1003843590
$2,316.21
in general payments reported to CMS, 2019-2025
24 companies · $25.35 in 2025
The $25.35 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,803 · 2020: $312 · 2021: $176 · 2025: $25.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $303.81 | 2019-2021 | |
| Astellas Pharma US INC | $221.76 | 2019 | |
| Pfizer INC. | $213.10 | 2019-2020 | |
| Echosens North America, INC. | $200.50 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.32 | 2019-2020 | |
| Braintree Laboratories, INC. | $165.34 | 2019-2021 | |
| Glaxosmithkline, LLC. | $134.14 | 2019-2020 | |
| Novo Nordisk INC | $128.55 | 2019-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $126.93 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.94 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.03 | 2019-2020 | |
| Neos Therapeutics, LP | $62.51 | 2019 | |
| Janssen Pharmaceuticals, INC | $59.63 | 2019 | |
| Janssen Biotech, INC. | $53.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $49.22 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $48.18 | 2019 | |
| Gilead Sciences, INC. | $45.83 | 2019-2020 | |
| Romark Laboratories, Lc | $32.89 | 2019 | |
| Allergan, INC. | $29.29 | 2020 | |
| Medtronic Minimed, INC. | $25.20 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.71 | 2019 | |
| Seqirus USA INC | $15.16 | 2019 | |
| Merck Sharp & Dohme LLC | $11.92 | 2019 | |
| Abbvie INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.